- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07876440
A Clinical Study of HH-1270 in Healthy Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HH-1270 Tablets in Healthy Chinese Participants
This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.
MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Xiyu Zhang
- Número de teléfono: 18701650516
- Correo electrónico: zhangxiyu@hhhbio.com
Ubicaciones de estudio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 100191
- Reclutamiento
- Peking University Third Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
- Weight: male ≥50.0 kg, female ≥45.0 kg, and body mass index (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
- Results of vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) at screening are normal or abnormal without clinical significance.
- Participants must agree to take adequate and effective contraceptive measures.
- Participants understand and comply with the study procedures, voluntarily participate, and sign the informed consent form (ICF).
Exclusion Criteria:
- Individuals with severe systemic diseases, infectious diseases, or mental disorders.
- Clinically significant electrocardiogram (ECG) abnormalities.
- History of clinically significant drug allergy or atopic allergic diseases.
- Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
- Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
- History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
- Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
- Blood donation ≥400 mL within 3 months before screening.
- Participation in another interventional clinical trial within 3 months before screening.
- Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
- Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
- Known or suspected history of allergy to any component of HH-1270 tablets or their excipients.
- Inability to accept standardized diet management at the study center.
- Participants who are breastfeeding or have a positive pregnancy test before the first dose.
- Participants deemed unsuitable for participation in the study by the investigator.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: HH-1270 group
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
|
Comparador de placebos: Placebo group
SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Periodo de tiempo: up to 15/21 days in SAD/MAD
|
Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
up to 15/21 days in SAD/MAD
|
|
Clinically significant abnormalities
Periodo de tiempo: up to 14/21 days in SAD/MAD
|
Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0. |
up to 14/21 days in SAD/MAD
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Area Under the Plasma Concentration Versus Time Curve (AUC)
Periodo de tiempo: up to 8/14 days in SAD/MAD
|
AUC of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Maximum Plasma Concentration (Cmax)
Periodo de tiempo: up to 8/14 days in SAD/MAD
|
Cmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Time to Reach Maximum Plasma Concentration (Tmax)
Periodo de tiempo: up to 8/14 days in SAD/MAD
|
Tmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Terminal Elimination Half-life (T1/2)
Periodo de tiempo: up to 8/14 days in SAD/MAD
|
T1/2 of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Plasma Clearance (CL/F)
Periodo de tiempo: up to 8/14 days in SAD/MAD
|
CL/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent volume of distribution(Vd/F)
Periodo de tiempo: up to 8/14 days in SAD/MAD
|
Vd/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
To evaluate the TBA level
Periodo de tiempo: up to 15/21 days in SAD/MAD
|
TBA level for each collection point |
up to 15/21 days in SAD/MAD
|
|
To evaluate the CP-1 level
Periodo de tiempo: up to 15/21 days in SAD/MAD
|
CP-1 level for each collection point |
up to 15/21 days in SAD/MAD
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To evaluate QTc change
Periodo de tiempo: up to 8 days in SAD
|
QTc values in each collection point |
up to 8 days in SAD
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- HH1270-101
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .